Skip to content

Application of case management model based on HAPA theory in patients with nonalcoholic fatty liver disease

Application of case management model based on HAPA theory in patients with nonalcoholic fatty liver disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086407
Enrollment
Unknown
Registered
2024-07-01
Start date
2023-01-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease

Interventions

Control group:Patients in the control group were provided with diet and exercise regimens. The patients and their families were educated about the disease, and classic cases were disseminated through
Experimental group:1 .pre-intention stage: through a variety of ways to let patients understand the disease, and its adverse consequences. 2. Intention stage: formulate diet and exercise plans and co
And let patients learn to make their own health plans and maintain healthy behaviors in the long term.

Sponsors

Health Medicine Center, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) meet the NAFLD diagnostic criteria established in the Clinical Practice Guidelines for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease in Primary Care and Endocrinology (Cusi et al., 2022), (2) be between the ages of 18 and 60, (3) have no neurological disorder and be capable of communicating and cooperating with researchers, (4) be capable of reading and able to use WeChat, sports bracelets, and other electronic devices, and (5) voluntarily agree to study participation and to provide written informed consent.

Exclusion criteria

Exclusion criteria: (1) any motor system injuries or movement contraindications, (2) any diseases of the brain, heart, lungs, or other vital organs, (3) diseases that would affect the implementation of proscribed diets, or (4) the use of blood lipid or enzyme lowering drugs during the study.

Design outcomes

Primary

MeasureTime frame
fatty liver improvement;Analyses of health behaviors;

Secondary

MeasureTime frame
BMI;biochemical indices;

Countries

China

Contacts

Public ContactYing Chen

the Second Affiliated Hospital of Chongqing Medical University

300492@hospital.cqmu.edu.cn+86 138 8335 6657

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026